This rapid, cheap, quantitative assay can now be utilised for rapidly assessing drug treatments and the potential pathogenicity of newly discovered FTD and ALS gene variants by quantifying their effect on TDP-43 and/or FUS localisation. This evidence concerns the gene FUS and frontotemporal dementia.